Abstract:Numerous peptides inhibit the entry of enveloped viruses into cells. Some of these peptides have been shown to inhibit multiple unrelated viruses. We have suggested that such broad-spectrum antiviral peptides share a property called interfacial activity; they are somewhat hydrophobic and amphipathic, with a propensity to interact with the interfacial zones of lipid bilayer membranes. In this study, we further tested the hypothesis that such interfacial activity is a correlate of broad-spectrum antiviral activity. In this study, several families of peptides, selected for the ability to partition into and disrupt membrane integrity but with no known antiviral activity, were tested for the ability to inhibit multiple diverse enveloped viruses. These include Lassa pseudovirus, influenza virus, dengue virus type 2, herpes simplex virus 1, and nonenveloped human adenovirus 5. Various families of interfacially active peptides caused potent inhibition of all enveloped viruses tested at low and submicromolar concentrations, well below the range in which they are toxic to mammalian cells. These membrane-active peptides block uptake and fusion with the host cell by rapidly and directly interacting with virions, destabilizing the viral envelope, and driving virus aggregation and/or intervirion envelope fusion. We speculate that the molecular characteristics shared by these peptides can be exploited to enable the design, optimization, or molecular evolution of novel broad-spectrum antiviral therapeutics.IMPORTANCE New classes of antiviral drugs are needed to treat the ever-changing viral disease landscape. Current antiviral drugs treat only a small number of viral diseases, leaving many patients with established or emerging infections to be treated solely with supportive care. Recent antiviral peptide research has produced numerous membrane-interacting peptides that inhibit diverse enveloped viruses in vitro and in vivo Peptide therapeutics are becoming more common, with over 60 FDA-approved peptides for clinical use. Included in this class of therapeutics is enfuvirtide, a 36-residue peptide drug that inhibits HIV entry/fusion. Due to their broad-spectrum mechanism of action and enormous potential sequence diversity, peptides that inhibit virus entry could potentially fulfill the need for new antiviral therapeutics; however, a better understanding of their mechanism is needed for the optimization or evolution of sequence design to combat the wide landscape of viral disease.

Virus Entry Inhibitors: Past, Present, and Future

Peptide-Based HIV Entry Inhibitors

Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells

Virus-Derived Peptides for Clinical Applications

Defeating Enemy Outside the Border-Development of Viral Entry Inhibitors

Broad-Spectrum Antiviral Entry Inhibition by Interfacially Active Peptides

Development Of Protein- And Peptide-Based Hiv Entry Inhibitors Targeting Gp120 Or Gp41

Development Of Small-Molecule Hiv Entry Inhibitors Specifically Targeting Gp120 Or Gp41

Triterpenoid-Mediated Inhibition of Virus-Host Interaction: is Now the Time for Discovering Viral Entry/Release Inhibitors from Nature?

Viral Entry Inhibitors Targeting Six-Helical Bundle Core Against Highly Pathogenic Enveloped Viruses with Class I Fusion Proteins.

Blocking Viral Entry: a Complementary Strategy for HIV Therapy

Current Progress in Antiviral Strategies.

Current Status of the Pharmacokinetics and Pharmacodynamics of HIV-1 Entry Inhibitors and HIV Therapy

Influenza Virus Cell Entry and Targeted Antiviral Development

Recent Progress of Novel Anti-Influenza Entry Inhibitors

Small-Molecule HIV Entry Inhibitors Targeting Gp120 and Gp41

Anti-virus reagents targeting the capsid protein assembly

Small-molecule HIV-1 Entry Inhibitors Targeting the Epitopes of Broadly Neutralizing Antibodies

Discovery and development of antiviral drugs

The successes and failures of HIV drug discovery

Peptide-based Fusion Inhibitors for Preventing the Six-helix Bundle Formation of Class I Fusion Proteins: HIV and Beyond